Seer (NASDAQ:SEER) Posts Earnings Results, Hits Expectations

Seer (NASDAQ:SEER) issued its earnings results on Wednesday. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.30), FiscalAI reports. The firm had revenue of $2.79 million during the quarter, compared to analysts’ expectations of $3.60 million. Seer had a negative net margin of 443.96% and a negative return on equity of 26.04%.

Here are the key takeaways from Seer’s conference call:

• Seer reaffirmed its full-year 2026 revenue guidance of $16 million to $18 million, saying it still expects momentum to build through the year despite a soft first quarter and continued NIH funding pressure.
• Q1 revenue fell to $2.8 million from $4.2 million a year ago, reflecting weak academic/government funding, heavier competitive pressure, and some disruption from a commercial leadership transition.
• The company said its scientific validation continues to accelerate, with 84 peer-reviewed publications, preprints, and reviews now supporting the Proteograph platform, up sharply from 42 a year ago.
• Seer highlighted major progress in population-scale studies, including the PRECISE-SG100K biobank program and other large cohorts, which management believes could help drive broader adoption and larger future revenue opportunities.
• The company emphasized strong cost discipline, as operating expenses fell to $18.2 million from $22.8 million a year earlier, while it ended Q1 with $219.5 million in cash and investments and said it has enough liquidity to reach cash-flow breakeven.

Seer Trading Down 2.7%

Shares of Seer stock traded down $0.05 during trading hours on Wednesday, reaching $1.77. The stock had a trading volume of 354,533 shares, compared to its average volume of 332,477. The stock’s 50 day moving average is $1.81 and its 200 day moving average is $1.90. Seer has a twelve month low of $1.65 and a twelve month high of $2.41. The firm has a market capitalization of $99.86 million, a PE ratio of -1.38 and a beta of 1.63.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SEER. Canaccord Genuity Group began coverage on Seer in a research note on Monday, May 4th. They set a “buy” rating and a $4.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Seer in a report on Tuesday, April 21st. Finally, TD Cowen raised Seer to a “strong-buy” rating in a report on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $4.00.

Hedge Funds Weigh In On Seer

Several institutional investors and hedge funds have recently modified their holdings of SEER. Goldman Sachs Group Inc. grew its holdings in Seer by 51.6% in the first quarter. Goldman Sachs Group Inc. now owns 170,897 shares of the company’s stock valued at $289,000 after purchasing an additional 58,173 shares during the period. Jane Street Group LLC grew its stake in Seer by 33.3% in the 1st quarter. Jane Street Group LLC now owns 254,174 shares of the company’s stock valued at $430,000 after acquiring an additional 63,432 shares during the period. Geode Capital Management LLC increased its holdings in Seer by 16.5% in the 2nd quarter. Geode Capital Management LLC now owns 509,727 shares of the company’s stock worth $1,091,000 after acquiring an additional 72,265 shares in the last quarter. XTX Topco Ltd purchased a new position in Seer during the second quarter valued at $172,000. Finally, Occudo Quantitative Strategies LP acquired a new stake in shares of Seer in the second quarter valued at about $25,000. Hedge funds and other institutional investors own 75.20% of the company’s stock.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.